NorthLinks Bio debuts with $34 million funding from RA Capital to advance HEX17, a broad-spectrum antiviral for respiratory illnesses.

NexCure, Inc. has launched with $19M in Series A funding to improve access to CAR-T and advanced therapeutic treatments in outpatient settings.

The inaugural S2S China Symposium reveals its 2026 finalists, highlighting ten innovative biotech teams set to pitch to global investors.

The U.S. District Court has ruled in favor of Biohaven and Yale, confirming a $4 million judgement against RA Capital and Avilar for trade secret theft.

Is APLD a good stock to buy? We came across a bullish thesis on Applied Digital Corporation on The Analyst’s Journal’s Substack by RA_Capital. In this article, we will summarize the bulls’ thesis on APLD. Applied Digital Corporation’s share was trading at $27.05 as of March 13th. APLD’s forward P/E was 526.32 according to Yahoo Finance. Applied Digital […]

Is MSTR a good stock to buy? We came across a bullish thesis on Strategy Inc on The Analyst's Journal’s Substack by RA_Capital. In this article, we will

Karyopharm Therapeutics has announced a $30 million private placement with RA Capital Management to bolster its oncology pipeline, potentially increasing funding with warrant exercises.

RA Capital Management, together with OMERS Life Sciences, announced a significant financing deal with ARS Pharma to boost their commercial endeavors. This innovative funding will support the growth of ARS Pharma's groundbreaking products.

RA Capital Management has officially closed its $120 million Planetary Health Fund, aimed at investing in sustainable solutions for global challenges.

Bambusa Therapeutics has successfully raised around $90 million in Series A funding to advance its bispecific antibody programs aimed at treating immunological and inflammatory disorders.